Depomed Reports Second Quarter 2010 Financial Results MENLO PARK, Calif., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today reported financial results for the second quarter ended June 30, 2010. Net income for the three months ended...

Depomed Receives Confirmation from Pfizer That No Infringement Suit to be Filed on DM-1796 NDA MENLO PARK, Calif., Aug. 3, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that pursuant to the Hatch-Waxman Act, the 45-day period for filing a patent infringement suit under...

Depomed to Announce Second Quarter 2010 Financial Results on August 5, 2010 MENLO PARK, Calif., July 29, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that it will release second quarter 2010 financial results after the market closes Thursday, August 5,...

Depomed Announces Receipt of a $10 Million Milestone Payment for DM-1796 MENLO PARK, Calif., June 28, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it has received a $10 million milestone payment from Abbott Products, Inc., its licensee of...

Depomed Announces Acceptance of New Drug Application for Investigational Postherpetic Neuralgia Treatment DM-1796 MENLO PARK, Calif., June 7, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that the New Drug Application (NDA) for DM-1796 was accepted by the U.S. Food and Drug Administration...